Format

Send to

Choose Destination
J Thorac Dis. 2018 Jan;10(1):219-227. doi: 10.21037/jtd.2017.12.30.

A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy.

Author information

1
Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, CA, USA.
2
Division of Oncology, Department of Medicine, Stanford University, Stanford, CA, USA.
3
Department of Medicine, University of Utah, Salt Lake City, UT, USA.
4
Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
5
Department of Oncology, Institut de Cancérologie de Lorraine, Nancy, France.
6
Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
7
Florida Hospital Cancer Institute, Orlando, FL, USA.

Abstract

Background:

Brain metastases are a common complication of advanced non-small cell lung cancer (NSCLC). Patients with brain metastases were excluded from the registration trials of bevacizumab that showed a survival benefit with the use of angiogenesis inhibition.

Methods:

In this study, we pooled data from two separate trials designed to evaluate the risk of central nervous system (CNS) hemorrhage in patients with stable treated brain metastases to look specifically at both the safety and efficacy of bevacizumab and pemetrexed when used as second-line treatment in NSCLC patients with stable treated brain metastases.

Results:

We report acceptable safety and promising efficacy from our analysis.

Conclusions:

Our study adds further evidence of safety of administering pemetrexed and bevacizumab to patients with stable brain metastases. There is increasing roles for systemic therapies to treat stable brain metastases for patients with advanced NSCLC.

KEYWORDS:

Brain metastases; bevacizumab; non-small cell lung cancer (NSCLC); pemetrexed

Conflict of interest statement

Conflicts of Interest: MA Gubens reports a consultancy relationship with Genentech not related to the current work; W Akerley reports past grant funding and fees for participation in review activities paid to his institution and past consulting fee or honorarium and travel support paid to him related to the current work, and past grants from the sponsors to his institution not related to the current work; CJ Langer reports an ongoing consultancy relationship with Lilly and Genentech not related to the current work; AD Colevas reports current grants or grants pending with Genentech to his institution not related to the current work; K Dragnev reports a past consultancy relationship with Genentech and Lilly not related to the current work; MA Socinski reports a grant to his institution to support the current work; HA Wakelee reports a grant to her institution to support the current work, as well as ongoing grants or grants pending to her institution not related to the current work. The other authors have no conflicts of interest to declare.

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center